Abstract
On February 24, 2021, the U.S. Food and Drug Administration (FDA) approved an efficacy supplement for HUMIRA (R) (adalimumab) injection to expand the ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
